Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

120%

6 of 5 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 3

2(33.3%)

Phase 2

2(33.3%)

Phase 4

2(33.3%)

6Total

Phase 3(2)

Phase 2(2)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01328002Phase 2Terminated

Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia

Role: collaborator

NCT01331109Phase 2Terminated

Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia

Role: collaborator

NCT01077375Phase 4Completed

Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia

Role: collaborator

NCT01014585Phase 4Completed

Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia

Role: collaborator

NCT01038349Completed

Applications for Methotrexate Optimization in Rheumatoid Arthritis

Role: lead

NCT00314249Phase 3Completed

Study of Milnacipran for the Treatment of Fibromyalgia

Role: collaborator

NCT00618956Phase 3Completed

A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring

Role: collaborator

All 7 trials loaded